FINAL PEER updated– The Swygert Axis: A New Paradigm in Cytokine-Histamine Signaling, Chronic Inflammatory Disease, and Immune Equilibrium

FINAL PEER – The Swygert Axis: A New Paradigm in Cytokine-Histamine Signaling, Chronic Inflammatory Disease, and Immune Equilibrium
Author: John Stephen Swygert

Abstract
The Swygert Axis integrates histamine receptors (H1-H4), cytokine dynamics, viral latency, and mast cell behavior into a unified model for chronic inflammatory disease, rooted in the Swygert Theory of Everything AO (STOE-AO). Based on lived experience and analysis, it posits chronic illness (e.g., long COVID) as a cumulative immune burden disrupting equilibrium. A diagnostic ratio and therapeutic roadmap using antihistamines, anti-cytokines, and antivirals are proposed, linking immune balance to celestial equilibrium.

I. Introduction
Surviving a severe immune collapse revealed to me a patterned dysfunction, not random chaos. Mainstream immunology details histamine, cytokines, and mast cells [Galli, 1993] but lacks a unifying model for chronic diseases like long COVID. The Swygert Axis, grounded in STOE-AO’s encoded substrate [cite FINAL PEER – The Encoded Substrate], reframes this as an equilibrium failure across immune signaling.

II. The Swygert Axis
The axis balances four histamine receptors:
  • H1: Inflammation, permeability [Simons, 1996].
  • H2: Tolerance, cardiac effects [Sachs, 1995].
  • H3: Neuroimmune signaling [Arrang, 1983].
  • H4: Mast cell modulation [Thurmond, 2004].
    Cytokines (e.g., IL-6, TNF-α) and latent viruses (e.g., HSV-1 [Kennedy, 2014]) interplay, with mast cells as regulators [Galli, 1993]. Equilibrium fails under cumulative burden (toxins, viral reactivation).
III. Cumulative Burden Model
Chronic disease stems from:
  • Environmental stressors (e.g., allergens).
  • Viral reactivation (e.g., EBV).
  • Cytokine feedback loops.
    We propose
    \frac{C}{I} \approx 1
    , where $ C $ is cytokine load and $ I $ is immune capacity, with
    C/I \approx 1.5
    in disease states (e.g., long COVID).
IV. Therapeutic Roadmap
  • Antihistamines: H1 blockers reduce inflammation [Simons, 1996]; H4 modulators stabilize mast cells [Thurmond, 2004].
  • Anti-Cytokines: Anti-IL-6, TNF-α agents calm loops [Hunter, 2019].
  • Antivirals: Acyclovir suppresses latency [Whitley, 1986].
  • Goal: Restore
    C/I \approx 1
    with low-toxicity targeting.
V. Conclusion
The Swygert Axis reframes chronic disease as an equilibrium breakdown, offering a diagnostic and therapeutic model. Future work will quantify
C/I
ratios, linking immune and celestial balance [cite FINAL – The Eclipse].

References
  • Simons, F.E.R. “Histamine and H1-Receptor Antagonists.” Springer, 1996.
  • Sachs, G., et al. “Histamine and Acid Secretion.” Gastroenterology, 1995.
  • Arrang, J.M., et al. “H3 Receptors and Neurotransmitter Release.” Nature, 1983.
  • Thurmond, R.L., et al. “H4 Receptor Opportunities.” Pharmacological Reviews, 2004.
  • Kennedy, P.G.E. “Herpes Simplex Virus Latency.” FEMS Microbiology Reviews, 2014.
  • Galli, S.J., et al. “Mast Cells in Disease.” New England Journal of Medicine, 1993.
  • Hunter, C.A., et al. “Cytokine Storms.” Nature Reviews Immunology, 2019.
  • Whitley, R.J. “Acyclovir Therapy.” New England Journal of Medicine, 1986.

Comments

Popular posts from this blog

OPEN SOURCE CIVILIAN WEATHER AND UAP NETWORK - DISH NETWORK SENTINEL TRILOGY - BOOKLET 2 OF 2

Core Storms: CMB Fragmentation and Transient Geodynamical Disruptions in the AO Framework - The Swygert Theory of Everything AO

Reorganization of the Periodic Table of Elements via The Swygert Theory of Everything AO